KT-474 (IRAK4 degrader) ✔️

Kymera Therapeutics

Confirmed correct on August 16, 2023 at ACS Fall National Meeting.

KT-474 is an IRAK4-specific degrader being developed by Kymera Therapeutics ( KYMR 0.00%↑) for the treatment of atopic dermatitis or hidradenitis suppurativa. It was recently evaluated in phase 1 (NCT04772885), with phase 2 trials planned for 4Q2023.